Related Experiment Videos
Postoperative chemoradiotherapy for gastric cancer
1Division of Hematology and Oncology, Department of Medicine, Cancer Center, Samsung Medical Center, Sunkyunkwan University School of Medicine, Seoul, Korea.
Summary
Postoperative chemoradiotherapy in gastric cancer patients after D2 lymph node dissection showed acceptable toxicity. Further studies are needed to determine if this adjuvant therapy improves survival or reduces relapse rates.
Area of Science:
- Oncology
- Gastrointestinal Surgery
- Radiation Oncology
Background:
- Gastric cancer management often involves multimodal therapy.
- Curative resection with D2 lymph node dissection is a standard surgical approach.
- Adjuvant therapy is explored to improve outcomes after surgery.
Purpose of the Study:
- To evaluate the feasibility and toxicity of postoperative chemoradiotherapy in gastric cancer patients.
- To assess initial outcomes including relapse patterns and survival rates.
Main Methods:
- Patients with resected gastric cancer (Stage IB-IV M0) received chemoradiotherapy.
- Chemotherapy included fluorouracil and leucovorin.
- Radiotherapy dose was 4500 cGy over 5 weeks with concurrent chemotherapy.
- Two additional chemotherapy cycles were administered post-radiotherapy.
Main Results:
- 229 out of 290 patients completed the planned chemoradiotherapy.
- Median follow-up was 49 months.
- Relapse occurred in 34% of patients (locoregional, peritoneal, distant).
- 5-year overall survival was 60% and relapse-free survival was 57%.
- Neutropenia was the primary toxicity, with acceptable overall tolerance.
Conclusions:
- Postoperative chemoradiotherapy is a feasible treatment option for gastric cancer patients following D2 dissection.
- The observed toxicities were manageable.
- The impact of this adjuvant therapy on long-term survival and relapse incidence requires further investigation.